Prulifloxacin is a synthetic fluoroquinolone antibacterial agent and a prodrug that is converted in the body to its active metabolite, ulifloxacin. It belongs to the quinolone/fluoroquinolone class of antibacterial compounds and has activity against a range of Gram-positive and Gram-negative bacteria.
Prulifloxacin is chemically characterized by a fluorinated quinolone core containing a piperazine substituent and a cyclic carbonate moiety. Its molecular formula is C₂₁H₂₀FN₃O₆S and its molecular weight is approximately 461.46 g/mol.
The API is primarily relevant to pharmaceutical manufacturing, analytical research, reference-standard applications, and development of oral antibacterial formulations.
Prulifloxacin belongs to the fluoroquinolone antibiotic class and is classified as a quinolone antibacterial. It is associated with the ATC antibacterial group J01MA17.
Prulifloxacin acts as a prodrug. After administration, it undergoes enzymatic conversion to ulifloxacin, the active antibacterial moiety. Ulifloxacin inhibits bacterial DNA replication through interference with bacterial DNA gyrase and topoisomerase IV, enzymes required for DNA replication and chromosome segregation.
This mechanism results in disruption of bacterial DNA processes and ultimately inhibits bacterial growth.
Prulifloxacin has been developed for oral antibacterial therapy and has been investigated and used in certain markets for bacterial infections, including urinary tract infections and other susceptible bacterial infections. PubChem identifies it as a fluoroquinolone antibiotic investigated for urinary tract infection.
For API manufacturing, Prulifloxacin is relevant to:
Prulifloxacin is generally supplied as a solid/crystalline powder. TCI reports the appearance as light orange to yellow to green powder to crystals and gives a reference melting point of approximately 220°C with decomposition.
The compound is reported as insoluble in water and soluble in dimethylformamide (DMF); TCI also reports it as insoluble in ether.
Prulifloxacin can be characterized using chromatographic and spectroscopic techniques including:
TCI specifies HPLC purity ≥98.0 area% and nonaqueous titration purity ≥98.0% for its research-grade material. These values should be treated as supplier-grade specifications rather than a universal pharmacopoeial API release limit.
Quality control of Prulifloxacin API should focus on identity, assay/purity, related substances, residual solvents, water content, elemental impurities, and microbiological quality where applicable to the intended pharmaceutical use.
Published analytical literature describes HPLC methods capable of determining Prulifloxacin together with multiple related impurities, supporting chromatographic impurity profiling during pharmaceutical development.
A patent describing preparation and purification of Prulifloxacin reports isolated material with HPLC purities ranging from approximately 98.05% to 99.55%, demonstrating the importance of chromatographic purity control during API processing.
Prulifloxacin is represented in PubChem as having an undefined stereocenter count of 1 for the standard record, while a separate PubChem record identifies an optically active (1R)-Prulifloxacin structure.
Therefore, stereochemical control should be addressed according to the specific API manufacturing route and applicable product specification rather than assuming that a single stereochemical specification applies universally.
Prulifloxacin is reported to be light-sensitive and heat-sensitive. TCI recommends storage in frozen conditions below 0°C.
Recommended handling considerations include:
Typical pharmaceutical API documentation may include:
Prulifloxacin API manufacturing requires controlled chemical synthesis, purification, drying, analytical testing, and appropriate environmental and storage controls. The final API should meet the agreed specification for identity, assay, purity, impurities, residual solvents, and other applicable quality attributes.
| Parameter | Specification |
|---|---|
| Appearance | white to off-white crystalline powder |
| Identification | IR & HPLC compliant |
| Assay (HPLC) | 98.0% – 102.0% |
| Loss on Drying | NMT 0.5% |
| Residue on Ignition | NMT 0.1% |
| Melting Point | Approx. 220°C, with decomposition |